Your browser is no longer supported. Please, upgrade your browser.
Settings
DXCM DexCom, Inc. daily Stock Chart
DXCM [NASD]
DexCom, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own1.70% Shs Outstand85.98M Perf Week18.64%
Market Cap6.90B Forward P/E- EPS next Y-0.31 Insider Trans-31.03% Shs Float83.22M Perf Month26.30%
Income-56.70M PEG- EPS next Q-0.10 Inst Own95.40% Short Float8.66% Perf Quarter-2.18%
Sales532.90M P/S12.94 EPS this Y-142.30% Inst Trans1.93% Short Ratio4.53 Perf Half Y-5.22%
Book/sh3.11 P/B25.79 EPS next Y70.50% ROA-17.60% Target Price86.39 Perf Year8.33%
Cash/sh1.48 P/C54.17 EPS next 5Y32.50% ROE-23.60% 52W Range47.92 - 96.38 Perf YTD34.36%
Dividend- P/FCF1532.55 EPS past 5Y5.70% ROI-25.60% 52W High-16.96% Beta0.43
Dividend %- Quick Ratio2.50 Sales past 5Y52.60% Gross Margin66.20% 52W Low67.01% ATR3.62
Employees1212 Current Ratio3.00 Sales Q/Q41.30% Oper. Margin-10.50% RSI (14)65.44 Volatility5.09% 4.76%
OptionableYes Debt/Eq0.02 EPS Q/Q57.70% Profit Margin-10.60% Rel Volume0.65 Prev Close80.21
ShortableYes LT Debt/Eq0.02 EarningsFeb 28 AMC Payout- Avg Volume1.59M Price80.03
Recom1.80 SMA2017.72% SMA5019.16% SMA2005.63% Volume344,131 Change-0.22%
Jan-03-17Downgrade Morgan Stanley Overweight → Equal-Weight $66
Dec-19-16Upgrade Oppenheimer Perform → Outperform
Nov-02-16Reiterated Canaccord Genuity Buy $100 → $70
Aug-03-16Reiterated The Benchmark Company Buy $86 → $106
Feb-24-16Reiterated The Benchmark Company Buy $105 → $86
Feb-08-16Downgrade Robert W. Baird Outperform → Neutral $100 → $74
Nov-02-15Initiated Morgan Stanley Overweight
Oct-15-15Upgrade Sterne Agee CRT Neutral → Buy
Oct-15-15Upgrade Leerink Partners Mkt Perform → Outperform
Sep-17-15Reiterated JP Morgan Overweight $95 → $120
Aug-06-15Reiterated Canaccord Genuity Buy $69 → $95
Jul-08-15Initiated Robert W. Baird Outperform $95
Apr-30-15Reiterated Oppenheimer Perform $64 → $69
Apr-20-15Reiterated Wedbush Outperform $73 → $80
Jan-27-15Reiterated Oppenheimer Perform $47 → $64
Aug-07-14Reiterated Canaccord Genuity Buy $40 → $48
Jun-17-14Reiterated Canaccord Genuity Buy $38 → $40
Jan-24-14Resumed Canaccord Genuity Buy $34 → $44
Jan-14-14Reiterated The Benchmark Company Buy $40 → $44
Nov-07-13Upgrade Northland Capital Under Perform → Market Perform
Jan-23-17 08:30AM  DexCom Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017 at 4:30 p.m. Eastern Time Business Wire
Jan-20-17 06:00PM  Cramers Exec Cut: This stock could be a triple threat un...
10:12AM  Alcobra Leads Biotech Movers Early Friday
06:23AM  The Pain Before the Gains: Cramer's 'Mad Money' Recap (Thursday 1/19/17)
Jan-19-17 06:53PM  Cramer Remix: Stop worrying! The Trump inauguration sell-off is not here to stay at CNBC
Jan-17-17 12:52PM  Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns
12:35PM  Bullish and Bearish Reversals in the Market
Jan-13-17 07:39PM  Here's Why Insulet Corporation Rose by Double-Digits Today at Motley Fool +25.91%
07:16PM  Cramer Remix: Why banks could have juicy dividends under Trump at CNBC
06:58PM  Cramer uncovers why Wall Street didnt see DexComs monster 25% move coming at CNBC
05:26PM  Why Sanchez Energy, DexCom, and Pandora Media Jumped Today at Motley Fool
04:53PM  DexCom shares soar after diabetes product gets Medicare approval at CNBC
04:12PM  DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage
03:27PM  Why DexCom, Inc. Stock Surged Higher Today at Motley Fool
11:50AM  4 Companies That Beat Friday the 13th
Jan-12-17 09:30PM  Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as "Durable Medical Equipment" under Medicare Part B Business Wire
09:42AM  DexCom, Inc. Value Analysis (NASDAQ:DXCM) : January 12, 2017
09:08AM  Johnson & Johnsons Diabetes Launch to Accelerate the Medical Device Business
Jan-11-17 11:56AM  DexCom: Look, but Don't Touch
09:04AM  DexCom Looking Forward to Strong Revenues in Q4 and 2016
07:31AM  DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : January 11, 2017
07:00AM  The launch of Dexcom Canada will reshape how Canadians living with diabetes access and use continuous glucose monitoring PR Newswire
Jan-10-17 08:37AM  DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits +7.28%
08:30AM  DexCom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2016 and Provides Initial 2017 Outlook Business Wire
Jan-03-17 06:14AM  Dexcom downgraded by Morgan Stanley
Dec-21-16 07:40AM  DexCom (DXCM) Gains FDA Approval for G5 Mobile CGM System
Dec-20-16 04:01PM  FDA Approval of Dexcoms Non-Adjunctive Indication Triggers a New Era in Diabetes Management Business Wire
Dec-19-16 08:50AM  These 3 Stocks Are Up Over 500% Over the Last 5 Years at Motley Fool
08:16AM  Analysts' Actions -- Bristol-Myers, Merck, United Technologies and More
08:00AM  DexCom Announces Upcoming Conference Presentation Business Wire
Dec-16-16 11:30AM  ETFs with exposure to DexCom, Inc. : December 16, 2016
Dec-13-16 12:24AM  Is Encana Corp (USA) (ECA) A Good Stock To Buy? at Insider Monkey
Dec-08-16 04:03PM  DEXCOM INC Files SEC form 8-K, Change in Directors or Principal Officers
Dec-02-16 11:01AM  SkyTides: Insulet's President Provided 'Critical Misinformation To Investors'
Dec-01-16 04:19PM  Is DexCom, Inc. (DXCM) A Good Stock To Buy? at Insider Monkey
02:44PM  6 stocks to watch at MarketWatch
Nov-15-16 03:19PM  Johnson & Johnson (JNJ), ACADIA Pharmaceuticals Inc. (ACAD): Healthcare Experts at March Altus Like These and Other Healthcare Stocks Prospects at Insider Monkey
08:00AM  DexCom Announces Upcoming Conference Presentation Business Wire
Nov-14-16 09:45AM  With Health Canada approval, Dexcom G5® Mobile CGM System is the First and Only Medical Device in North America for Making Daily Diabetes Decisions Without Painful Fingersticks PR Newswire +5.54%
09:45AM  With Health Canada approval, Dexcom G5® Mobile CGM System is the First and Only Medical Device in North America for Making Daily Diabetes Decisions Without Painful Fingersticks CNW Group
Nov-11-16 01:14PM  DexCom, Inc. (Nasdaq: DXCM) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Nov-10-16 01:24PM  Dexcom and Major League Soccer AT&T Rookie of the Year Jordan Morris Kick-off Partnership to Help Those Living with Diabetes PR Newswire
10:26AM  DexCom (DXCM) Incurs Wider Loss in Q3, Beats on Revenue
08:30AM  NIH-funded International Diabetes Closed Loop (IDCL) Trial to Combine Technologies from Tandem Diabetes Care, Dexcom and TypeZero Business Wire
Nov-05-16 01:04PM  DEXCOM INC Financials
Nov-04-16 12:37PM  ETFs with exposure to DexCom, Inc. : November 4, 2016
Nov-03-16 09:54AM  DexCom, Inc. :DXCM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
Nov-02-16 03:02PM  Here's Why Insulet Corporation Is Plunging Today at Motley Fool -19.24%
01:23PM  Here's Why DexCom, Inc. Is Plunging Today at Motley Fool
02:51AM  Edited Transcript of DXCM earnings conference call or presentation 1-Nov-16 8:30pm GMT
Nov-01-16 04:49PM  DexCom reports 3Q loss
04:07PM  DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  DexCom, Inc. Reports Third Quarter 2016 Financial Results Business Wire
07:07AM  Q3 2016 DexCom Inc Earnings Release - After Market Close
Oct-31-16 08:52AM  Medical Product Nov 1 Earnings Lineup: CERN, IDXX, DXCM, BIO
Oct-25-16 07:48AM  Think You've Seen Crazy Valuations? You Haven't Seen These 3 Stocks at Motley Fool
Oct-20-16 08:05AM  Actor Derek Theler and Dexcom Take Center Stage to Raise Awareness of Diabetes PR Newswire
Oct-18-16 10:14AM  ETFs with exposure to DexCom, Inc. : October 18, 2016
08:00AM  DexCom Announces Upcoming Conference Presentations Business Wire
Oct-06-16 09:46AM  ETFs with exposure to DexCom, Inc. : October 6, 2016
09:13AM  How DexCom Can Fight Back Against Medtronic's Artificial Pancreas at Motley Fool
Oct-04-16 10:46AM  New Strong Sell Stocks for October 4th
Oct-02-16 02:27PM  This Could Be the Biggest Breakthrough Ever for the 1.25 Million People With Type 1 Diabetes at Motley Fool
Sep-30-16 10:29AM  DexCom, Inc. Value Analysis (NASDAQ:DXCM) : September 30, 2016
Sep-29-16 08:32AM  DexCom, Inc. breached its 50 day moving average in a Bearish Manner : DXCM-US : September 29, 2016
Sep-27-16 08:00AM  DexCom Schedules Third Quarter 2016 Earnings Release and Conference Call for November 1, 2016 at 4:30 p.m. Eastern Time Business Wire
Sep-22-16 10:59AM  ETFs with exposure to DexCom, Inc. : September 22, 2016
Sep-14-16 10:01AM  BTIG Moves To Neutral On DexCom, But Says Shares Are Not Overvalued
Sep-07-16 04:07PM  Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent Diabetes is Now Available in Germany PR Newswire
Sep-06-16 10:25AM  ETFs with exposure to DexCom, Inc. : September 6, 2016
Sep-04-16 02:05PM  How Google Plans to Reinvent Healthcare at Motley Fool
Sep-01-16 04:30PM  DexCom Announces Upcoming Conference Presentation Business Wire
Aug-23-16 11:44AM  ETFs with exposure to DexCom, Inc. : August 23, 2016
Aug-15-16 05:34PM  Medtronic Launches MiniMed 630G, Expands in Diabetic Care (revised)
10:15AM  Medtronic Launches MiniMed 630G, Expands in Diabetic Care
Aug-09-16 01:32PM  ETFs with exposure to DexCom, Inc. : August 9, 2016
Aug-08-16 11:42AM  DexCom, Inc. :DXCM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016
08:10AM  DexCom Launches New Clinic Portal for the DexCom CLARITY® Diabetes Management Solution PR Newswire
Aug-05-16 06:58PM  Cramers Exec Cut: How Nike plans to win big in Rio
06:00AM  Jim Cramer's Top Takeaways: Johnson Controls, DexCom
Aug-04-16 07:10PM  Cramer Remix: This could make Apple roar higher at CNBC
Aug-03-16 11:18AM  DexCom (DXCM) Q2 Loss Wider than Expected, Stock Down
08:00AM  DexCom Announces Upcoming Conference Presentations Business Wire
Aug-02-16 07:21PM  Edited Transcript of DXCM earnings conference call or presentation 2-Aug-16 8:30pm GMT
05:01PM  DexCom reports 2Q loss
04:06PM  DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  DexCom, Inc. Reports Second Quarter 2016 Financial Results Business Wire
07:07AM  Q2 2016 DexCom Inc Earnings Release - After Market Close
Aug-01-16 08:07AM  Look at Aug 2 Medical Instrument Earnings: IDXX, DXCM, CGNT
Jul-22-16 01:01PM  DexCom Says FDA Advisory Committee Votes For Its Non-Adjunctive Label For G5 Mobile CGM System
10:05AM  [$$] Dexcom Shares Rise After FDA Panel Vote at The Wall Street Journal
06:05AM  FDA Advisory Committee Votes in Favor of Non-Adjunctive Label for DexCom G5 Mobile CGM System PR Newswire
Jul-20-16 12:20PM  ETFs with exposure to DexCom, Inc. : July 20, 2016
08:30AM  Strength Seen in Dexcom (DXCM) Soars: Stock Soars 6.2%
Jul-19-16 05:50PM  Why MGIC Investment, Dexcom, and F5 Networks Jumped Today at Motley Fool +6.20%
12:45PM  Why These Stocks Are Gaining Ground on Tuesday? at Insider Monkey
10:19AM  Dexcom Says FDA Published Briefing Documents Before Advisory Committee Meeting
08:32AM  FDA Posts Briefing Documents Ahead of Advisory Committee Meeting Business Wire
Jul-06-16 08:30AM  Country Music Star Eric Paslay Partners with Dexcom to Share His Story and Help Others Living with Diabetes PR Newswire
Jul-01-16 08:00AM  DexCom Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016 at 4:30 p.m. Eastern Time Business Wire
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring; and DexCom G5 Mobile, a continuous glucose monitoring system. The company's in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers; and sensor augmented insulin pumps. The company markets its products directly to endocrinologists, physicians, and diabetes educators. It has collaboration agreements with Animas Corporation and Tandem Diabetes Care, Inc. The company was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROPER JESSSVP, CFOJan 18Sale85.013,012256,05112,785Jan 20 06:37 PM
SAYER KEVIN RPresident & CEOJan 17Option Exercise8.7910,00087,900309,391Jan 19 08:33 PM
SAYER KEVIN RPresident & CEOJan 17Sale85.9410,000859,362299,391Jan 19 08:33 PM
VALDES JORGE ACTOJan 13Option Exercise8.9726,100234,08082,334Jan 18 07:37 PM
LISTER JOHNGeneral Manager, EMEAJan 13Option Exercise8.8515,000132,75085,598Jan 18 07:38 PM
VALDES JORGE ACTOJan 13Sale80.0026,1002,088,00072,334Jan 18 07:37 PM
LISTER JOHNGeneral Manager, EMEAJan 13Sale79.3615,0001,190,40070,598Jan 18 07:38 PM
Balo Andrew KEVP, Clinical and RegulatoryJan 10Option Exercise9.803,20031,360109,545Jan 12 07:21 PM
Balo Andrew KEVP, Clinical and RegulatoryJan 10Sale62.863,200201,152106,345Jan 12 07:21 PM
VALDES JORGE ACTOJan 09Option Exercise7.3710,90080,29179,334Jan 11 07:31 PM
LISTER JOHNGeneral Manager, EMEAJan 09Option Exercise8.853,00026,55073,598Jan 11 07:33 PM
VALDES JORGE ACTOJan 09Sale63.0210,900686,90572,334Jan 11 07:31 PM
LISTER JOHNGeneral Manager, EMEAJan 09Sale63.023,000189,04670,598Jan 11 07:33 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerDec 23Sale62.173,182197,83119,097Dec 28 08:12 PM
ROPER JESSSVP, CFODec 14Sale64.142,442156,61915,797Dec 16 07:20 PM
VALDES JORGE ACTODec 09Option Exercise7.6010,00076,04376,259Dec 13 04:21 PM
VALDES JORGE ACTODec 09Sale64.8110,000648,07972,334Dec 13 04:21 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Nov 23Sale70.3210,300724,260110,409Nov 28 07:27 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerNov 23Sale70.193,182223,35022,279Nov 28 07:29 PM
LISTER JOHNGeneral Manager, EMEANov 09Sale62.503,417213,56370,598Nov 14 06:31 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerOct 24Sale81.123,182258,11025,461Oct 26 05:07 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Oct 24Sale81.9510,300844,065120,709Oct 26 05:08 PM
ROPER JESSSVP, CFOOct 24Sale80.752,471199,54474,215Oct 26 05:08 PM
Balo Andrew KEVP, Clinical and RegulatoryOct 19Sale82.314,997411,303106,345Oct 20 07:55 PM
SAYER KEVIN RPresident & CEOOct 14Sale81.877,000573,101299,891Oct 17 08:25 PM
VALDES JORGE ACTOOct 10Option Exercise7.6311,00083,93083,334Oct 12 08:57 PM
VALDES JORGE ACTOOct 10Sale84.4211,000928,57972,334Oct 12 08:57 PM
LISTER JOHNGeneral Manager, EMEAOct 10Sale84.413,560300,50874,015Oct 12 08:59 PM
Balo Andrew KEVP, Clinical and RegulatoryOct 05Sale82.555,000412,750111,342Oct 07 05:10 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerSep 23Sale93.973,182299,00028,643Sep 27 08:14 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Sep 23Sale94.0010,300968,196131,009Sep 27 08:15 PM
ROPER JESSSVP, CFOSep 22Sale93.992,470232,15576,686Sep 23 07:52 PM
Balo Andrew KEVP, Clinical and RegulatorySep 21Sale92.875,000464,366116,342Sep 22 06:38 PM
SAYER KEVIN RPresident & CEOSep 14Sale91.797,000642,527306,891Sep 16 05:35 PM
VALDES JORGE ACTOSep 12Sale92.067,071650,9653,499Sep 13 08:30 PM
SKYLER JAY SDirectorSep 12Sale93.0010,000930,0000Sep 14 08:46 PM
KAHN BARBARADirectorSep 12Sale92.905,000464,51224,304Sep 14 08:44 PM
VALDES JORGE ACTOSep 09Option Exercise7.6312,00091,560103,667Sep 13 08:30 PM
SKYLER JAY SDirectorSep 09Sale94.0725,0002,351,78817,246Sep 13 08:51 PM
LISTER JOHNGeneral Manager, EMEASep 09Sale93.653,560333,39287,214Sep 13 08:33 PM
LISTER JOHNGeneral Manager, EMEASep 09Sale93.653,560333,39287,214Sep 13 08:32 PM
VALDES JORGE ACTOSep 09Sale93.6612,0001,123,90991,667Sep 13 08:30 PM
GREGG TERRANCE HExecutive ChairmanSep 08Sale95.595,145491,83065,882Sep 09 08:48 PM
Balo Andrew KEVP, Clinical and RegulatorySep 07Option Exercise3.194,99915,947135,009Sep 09 08:49 PM
FOLETTA MARK GDirectorSep 07Sale94.631,800170,32515,643Sep 09 08:50 PM
GREGG TERRANCE HExecutive ChairmanSep 07Sale95.015,595531,57171,027Sep 09 08:48 PM
Balo Andrew KEVP, Clinical and RegulatorySep 07Sale94.454,999472,156130,010Sep 09 08:49 PM
LORD JONATHAN T MDDirectorSep 01Sale91.5010,000915,00052,820Sep 06 07:34 PM
GREGG TERRANCE HExecutive ChairmanAug 30Sale92.1410,000921,35676,622Sep 01 08:05 PM
Balo Andrew KEVP, Clinical and RegulatoryAug 24Option Exercise3.195,00015,950134,979Aug 26 04:49 PM
Balo Andrew KEVP, Clinical and RegulatoryAug 24Sale91.725,000458,600129,979Aug 26 04:49 PM
GREGG TERRANCE HExecutive ChairmanAug 24Sale92.7210,000927,15186,622Aug 26 06:36 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerAug 23Sale90.893,182289,22431,825Aug 25 04:35 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Aug 23Sale90.7410,300934,588151,622Aug 25 04:33 PM
GREGG TERRANCE HExecutive ChairmanAug 23Sale91.1110,000911,11596,622Aug 24 08:07 PM
GREGG TERRANCE HExecutive ChairmanAug 22Sale90.5110,000905,108106,622Aug 24 08:07 PM
SKYLER JAY SDirectorAug 19Sale90.7725,0002,269,23342,246Aug 22 09:27 PM
GREGG TERRANCE HExecutive ChairmanAug 19Sale90.6320,0001,812,516116,622Aug 22 09:26 PM
ALTMAN STEVEN RDirectorAug 19Sale90.913,500318,17715,142Aug 23 08:35 PM
GREGG TERRANCE HExecutive ChairmanAug 18Sale90.7720,0001,815,326136,622Aug 22 09:26 PM
SAYER KEVIN RPresident & CEOAug 15Sale90.787,000635,473335,227Aug 17 07:31 PM
GREGG TERRANCE HExecutive ChairmanAug 15Sale91.0114,9421,359,858156,622Aug 17 07:31 PM
LORD JONATHAN T MDDirectorAug 12Sale90.505,000452,503126,373Aug 15 07:50 PM
GREGG TERRANCE HExecutive ChairmanAug 11Sale91.0310,900992,280171,564Aug 15 07:49 PM
LORD JONATHAN T MDDirectorAug 11Sale90.785,000453,896131,373Aug 15 07:50 PM
Balo Andrew KEVP, Clinical and RegulatoryAug 10Option Exercise3.195,00015,950134,979Aug 12 07:10 PM
Balo Andrew KEVP, Clinical and RegulatoryAug 10Sale90.265,000451,300129,979Aug 12 07:10 PM
VALDES JORGE ACTOAug 09Option Exercise7.6332,000244,160123,667Aug 11 07:29 PM
SAYER KEVIN RPresident & CEOAug 09Option Exercise8.7920,000175,800362,227Aug 11 07:29 PM
GREGG TERRANCE HExecutive ChairmanAug 09Sale91.1035,0003,188,623182,464Aug 11 09:21 PM
GREGG TERRANCE HExecutive ChairmanAug 09Sale91.002,168197,288451,486Aug 11 09:21 PM
LISTER JOHNGeneral Manager, EMEAAug 09Sale91.073,560324,21790,774Aug 11 07:30 PM
SAYER KEVIN RPresident & CEOAug 09Sale90.9820,0001,819,552342,227Aug 11 07:29 PM
VALDES JORGE ACTOAug 09Sale91.0632,0002,913,97891,667Aug 11 07:29 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Aug 08Option Exercise11.33445161,922Aug 09 09:27 PM
KAHN BARBARADirectorAug 08Sale90.526,000543,13129,304Aug 10 09:25 PM
VALDES JORGE ACTOAug 05Option Exercise9.8025,000245,000116,667Aug 09 09:26 PM
GREGG TERRANCE HExecutive ChairmanAug 05Sale91.2920,0001,825,798217,464Aug 09 09:26 PM
VALDES JORGE ACTOAug 05Sale91.2225,0002,280,37591,667Aug 09 09:26 PM
MOY JEFFREYSVP, OperationsAug 01Sale93.0010,000930,00012,599Aug 02 08:35 PM
MOY JEFFREYSVP, OperationsJul 29Sale91.005,000455,00022,599Aug 02 08:35 PM
Balo Andrew KEVP, Clinical and RegulatoryJul 27Option Exercise3.195,00015,950134,979Jul 28 08:20 PM
Balo Andrew KEVP, Clinical and RegulatoryJul 27Sale88.145,000440,700129,979Jul 28 08:20 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerJul 25Sale87.313,182277,82235,007Jul 26 07:02 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jul 25Sale87.3310,300899,473161,918Jul 26 07:03 PM
MOY JEFFREYSVP, OperationsJul 22Sale88.4810,000884,80027,599Jul 26 07:03 PM
MOY JEFFREYSVP, OperationsJul 19Sale85.005,000425,00037,599Jul 21 07:12 PM
MOY JEFFREYSVP, OperationsJul 19Sale83.007,843650,96976,333Jul 21 07:12 PM
Balo Andrew KEVP, Clinical and RegulatoryJul 13Option Exercise3.195,00015,950134,979Jul 14 05:17 PM
SAYER KEVIN RPresident & CEOJul 13Sale79.927,000559,457342,227Jul 14 05:17 PM
Balo Andrew KEVP, Clinical and RegulatoryJul 13Sale80.125,000400,600129,979Jul 14 05:17 PM
VALDES JORGE ACTOJul 11Option Exercise7.6332,000244,160123,667Jul 12 06:05 PM
LISTER JOHNGeneral Manager, EMEAJul 11Sale79.353,560282,49494,334Jul 12 06:05 PM
VALDES JORGE ACTOJul 11Sale79.3632,0002,539,56591,667Jul 12 06:05 PM
Balo Andrew KEVP, Clinical and RegulatoryJun 29Option Exercise3.195,00015,950134,979Jul 01 05:48 PM
MOY JEFFREYSVP, OperationsJun 29Sale80.004,557364,56050,442Jul 01 05:49 PM
Balo Andrew KEVP, Clinical and RegulatoryJun 29Sale78.105,000390,500129,979Jul 01 05:48 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jun 23Sale77.4010,300797,189172,218Jun 27 05:03 PM
Balo Andrew KEVP, Clinical, RegulatoryJun 20Option Exercise3.1955,000175,450184,979Jun 20 08:23 PM
Balo Andrew KEVP, Clinical, RegulatoryJun 20Sale75.0055,0004,125,000129,979Jun 20 08:23 PM